多参数磁共振成像与前列腺特异性膜抗原PET/CT在局限性前列腺癌患者中检测性能的比较:系统评价与Meta分析
该Meta分析纳入2016至2022年39项研究共3630例患者,比较PSMA PET与mpMRI对局限性前列腺肿瘤的检测及T分期的诊断性能。PSMA PET对局限性肿瘤及T3a、T3b分期的汇总敏感性与mpMRI无显著差异(P>0.05),但亚组分析中18F-DCFPyL PET的汇总敏感性高于mpMRI(相对危险度1.10,95%CI 1.03-1.17,P<0.01)。
要点
- PSMA PET与mpMRI对局限性前列腺肿瘤及T3a、T3b分期的汇总敏感性无显著差异(P>0.05)。
- 放射性示踪剂亚组分析中,18F-DCFPyL PET的汇总敏感性高于mpMRI(相对危险度1.10,95%CI 1.03-1.17,P<0.01)。
- 共纳入39项研究、3630例患者,数据来自2016至2022年。
核心结论
- 该Meta分析发现,18F-DCFPyL PET在检测局限性前列腺肿瘤方面优于mpMRI,而PSMA PET对局限性前列腺肿瘤及T分期的检测性能与mpMRI相当。
研究设计与样本
- 系统检索PubMed/MEDLINE与Cochrane Library数据库,纳入2016至2022年的39项研究,共3630例患者。
- 以病理分析验证的汇总敏感性与特异性计算并比较PSMA PET与mpMRI两种影像工具的差异。
主要发现
- PSMA PET对局限性前列腺肿瘤的汇总敏感性为0.84(95%CI 0.83-0.86),mpMRI为0.84(95%CI 0.78-0.89),两者无显著差异(P>0.05)。
- PSMA PET对T3a分期的汇总敏感性为0.61(95%CI 0.39-0.79),mpMRI为0.67(95%CI 0.52-0.80),两者无显著差异(P>0.05)。
- PSMA PET对T3b分期的汇总敏感性为0.62(95%CI 0.46-0.76),mpMRI为0.60(95%CI 0.45-0.73),两者无显著差异(P>0.05)。
- 放射性示踪剂亚组分析中,18F-DCFPyL PET的汇总敏感性高于mpMRI(相对危险度1.10,95%CI 1.03-1.17,P<0.01)。
关键数值与推荐
- PSMA PET对局限性前列腺肿瘤的汇总敏感性为0.84(95%CI 0.83-0.86)。
- mpMRI对局限性前列腺肿瘤的汇总敏感性为0.84(95%CI 0.78-0.89)。
- PSMA PET对T3a、T3b分期的汇总敏感性分别为0.61(95%CI 0.39-0.79)与0.62(95%CI 0.46-0.76)。
- mpMRI对T3a、T3b分期的汇总敏感性分别为0.67(95%CI 0.52-0.80)与0.60(95%CI 0.45-0.73)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Multiparametric MRI (mpMRI) has been promoted as an auxiliary diagnostic tool for prostate biopsy. However, prostate-specific membrane antigen (PSMA) including 68 Ga-PSMA-11, 18 F-DCFPyL, and 18 F-PSMA-1007 applied PET/CT imaging was an emerging diagnostic tool in prostate cancer patients for staging or posttreatment follow-up, even early detecting. Many studies have used PSMA PET for comparison with mpMRI to test the diagnostic ability for early prostate cancer. Unfortunately, these studies have shown conflicting results. This meta-analysis aimed to compare the differences in diagnostic performance between PSMA PET and mpMRI for detecting and T staging localized prostatic tumors. METHODS: This meta-analysis involved a systematic literature search of PubMed/MEDLINE and Cochrane Library databases. The pooling sensitivity and specificity of PSMA and mpMRI verified by pathological analysis were calculated and used to compare the differences between the 2 imaging tools. RESULTS: Overall, 39 studies were included (3630 patients in total) from 2016 to 2022 in the current meta-analysis and found that the pooling sensitivity values for localized prostatic tumors and T staging T3a and T3b of PSMA PET were 0.84 (95% confidence interval [CI], 0.83-0.86), 0.61 (95% CI, 0.39-0.79), and 0.62 (95% CI, 0.46-0.76), respectively, whereas those of mpMRI were found to be 0.84 (95% 0.78-0.89), 0.67 (95% CI, 0.52-0.80), and 0.60 (95% CI, 0.45-0.73), respectively, without significant differences ( P > 0.05). However, in a subgroup analysis of radiotracer, the pooling sensitivity of 18 F-DCFPyL PET was higher than mpMRI (relative risk, 1.10; 95% CI, 1.03-1.17; P < 0.01). CONCLUSIONS: This meta-analysis found that whereas 18 F-DCFPyL PET was superior to mpMRI at detecting localized prostatic tumors, the detection performance of PSMA PET for localized prostatic tumors and T staging was comparable to that of mpMRI.
引用
- Wang YF, Lo CY, Chen LY, et al. Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2023. PMID: 37145456. doi:10.1097/RLU.0000000000004646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。